[1] | Baigent A, Lashen H. Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. Fertility and Sterility, 2011; 95:2429 e5-e7. |
[2] | Jones GL, Palep-Singh M, Lwsfwe WL, Balen AH, Jenkinson C, Campbell MJ, Lashen H. Do South Asian women with PCOS have poorer health related quality of life than Caucasian women with PCOS? A comparative cross sectional study. Helath Qual Life Outcomes, 2010; 8;149-152. |
[3] | Lashen H. Role of metformin in the management of polycystic ovary syndrome. Therapeutic advances in Endocrinology and metabolism. 2010;1:117-128. |
[4] | Roberts AL, Lashen H. Tibolone as a hormone replacement in women with endometriosis after bilateral oophorectomy. Int J Gynaecol Obstet 2010; 111: 183. |
[5] | Kelly CJ, Stenton SR, Lashen H. Insulin like growth factor binding protein 1 in PCOS: a systematic review and meta-analysis. Hum Reprod Update (Epub ahead of print) July 2010. |
[6] | Moores KL, Keriakos RH, Anumba DO, Connor ME, Lashen H. Management challenges of a live 12-week sub-hepatic intra-abdominal pregnancy. BJOG. 2010;117:365-8. |
[7] | Bonnett T and Lashen H. A case of acute post-laparoscopy bowel hypermotility and treatment with hyocine butylbromide. Journal of Perioperative Practice 2009; 19:436-7. |
[8] | Bayley TM, Slade P, Lashen H. Relationships between attachment, appraisal, coping and adjustment in men and women experiencing infertility concerns. Human Reproduction 2009;24:2827-37. |
[9] | Ghobadi C, Amer S, Lashen H, Lennard MS, Ledger WL, Rostami-Hodjegan A. Evaluation of the relationship between plasma concentrations of en-and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate. Fertil Steril 2009;91:1135-40. |
[10] | Stevenson TL, Lashen H. Empty follicle syndrome: the reality about a controversial syndrome, a systematic review. Fertility Sterility. 2008;90:691-8.. |
[11] | Slade P, O'Neill C, Simpson AJ, Lashen H. The relationship between perceived stigma, disclosure pattern, support and distress in new attendees at an infertility clinic. Human Reproduction. 2007;22:2309-17. |
[12] | Mohamed KA, Davies WA, Lashen H. Dynamics of pituitary down-regulation and ovarian response to controlled stimulation in in vitro fertilisation cycles. Fertility Sterility. 2007;87:433-5. |
[13] | Mohamed KA, Davies WA, Lashen H. Antimullerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertility Sterility. 2006;86:1515-7. |
[14] | Mohamed KA, Davies WA, Lashen H. Effects of gonadotrophin-releasing hormone agonist and antagonist on steroidogenesis of low responders undergoing in vitro fertilisation. Gynecol Endocrinol. 2006;22:57-62. |
[15] | Birch MP, Lashen H, Agrawal S, Messenger AG. Female pattern hair loss, sebum excretion and the end organ response to androgens. British J of Dermatology. 2006;154:85-89. |
[16] | McIlveen M, Lok D, Pritchard J, Lashen H. Modern embryo transfer catheters and pregnancy outcome. Fertility Sterility. 2005;84:996-1000. |
[17] | Reeves L, Lashen H, Pacey A. Endometriosis affects sperm-endosalpengeal interaction. Human Reproduction. 2005;20:448-51. |
[18] | Mohamed K, Davies WAR, Allsop J, Lashen H. Agonist "flare-up" versus antagonist in the management of poor responders undergoing in vitro fertilisation treatment. Fertility Sterility. 2005;83:331-5. |
[19] | Lashen H, Fears K, Sturdee D. Obesity is associated with increased risk of early and recurrent miscarriage: matched case control study. Human Reproduction. 2004;19:1644-6. |
[20] | Cheong Y.C, Abdullahi H, Lashen H, Fairlie F. Can formal education and training improve the outcome of instrumental delivery? Eur J Obs Gyn Reprod Biol. 2004;113:139-44. |
[21] | Jones, GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, Mulgrew NC, Shepherd KE, Wilkinson NH, Singh M, Balen A, Lashen H, Ledger W. The polycystic ovary syndrome Health-related questionnaire (PCOSQ): a validation. Hum Reprod. 2004;19:371-7 |
[22] | Elliot J, Connor M, Lashen H. The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstet Gynaecol Scandinavica. 2003;82:1112-9. |
[23] | Lock D, Prichard J, Lashen H. Successful treatment of empty follicle syndrome by triggering endogenous LH surge using GnRH agonist in an antagonist down-regulated IVF cycle. Hum Reprod 2003;18:1116-22. |
[24] | Lashen H, Fear K, Sturdee D. Trends in the management of breech presentation at term; experience in a district General Hospital over a 10 year period. Acta Obstet Gynaecol Scandinavica 2002;81:1116-1122. |
[25] | Lashen H, Afnan M, McDougall L, Clark P. Prediction of over-response to controlled ovarian stimulation in intrauterine insemination programme. Hum Reprod 1999;14:2751-2754. |
[26] | Lashen H, Afnan M, Kennefik A. Early resort to ovarian stimulation improves the cost-effectiveness of the donor insemination programme. Hum Reprod 1999;14:1983-1988. |
[27] | Lashen H, Afnan M, Sharif K. A controlled comparison of ovarian response to controlled stimulation in first generation Asian women vs. white Caucasians undergoing in vitro fertilisation. BJOG 1999;106:407-409. |
[28] | Lashen H, Ledger L, Lopez-Bernal A, Barlow D. Poor responders to ovulation induction: is proceeding to in vitro fertilisation worthwhile? Hum Reprod 1999;14:964-969. |
[29] | Lashen H, Ledger W, Bernal A, Barlow D. Extremes of body mass index do not adversely affect the outcome of superovulation and in vitro fertilisation. Hum Reprod 1999;14:712-715. |
[30] | El-Gendy M, Holder R, Lashen H, Sharif K, Affifi Y, Lenton W, Afnan M Reducing the dose of gonadotrophin-releasing hormone agonist (GnRHa) on starting the ovarian stimulation; effect on ovarian response and in vitro fertilisation outcome. Human Reproduction. 1998;13:2382-2385. |
[31] | Lashen H, Ledger W., Lopez-Bernal A, Evans B, and Barlow D. Superovulation with a high gonadotrophin dose for in vitro fertilisation: is it effective? Journal of Assisted Reproduction and Genetics. 1998;15:438-443. |
[32] | Lashen H, Afnan M. Manipulating the gonadotrophin dose in controlled ovarian hyperstimulation for IVF and its effect on ovarian response. The Egyptian Journal of Fertility and Sterility. 1998; 2:31-36. |
[33] | Sinclair L, Morgan C, Lashen H, Afnan M, and Sharif K. Nurses performing embryo transfer: the development and results of the Birmingham experience. Human Reproduction. 1998;13:699-702. |
[34] | Sharif K, Afnan M, Lashen H, El-Gendy M, Morgan C, Sinclair L. Is bed rest following embryo transfer necessary? Fertility Sterility. 1998;69:478-81. |
[35] | Sharif K, El-Gendy M, Lashen H, Afnan M. Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome. British Journal of Obstetrics and Gynaecology. 1998;105:107-112. |
[36] | Sharif K, Afnan M, Khalaf Y, Bilalis D, Lashen H. Ultrasound prediction of follicular volume during ovulation stimulation. Middle East Fertility Society Journal. 1997;2:53-56. |
[37] | Lashen H, Ledger W, Davies WAR, Smith R. Oocyte release in luteinized unruptured follicle with a second dose of hCG. Middle East Fertility Society Journal. 1996;3:226-229. |
[38] | Lashen H, Ledger W. Management of poor responders in IVF. Hum Reprod [letter] 1999;14:1919. |
[39] | Lashen H, Ledger W. Effect of agonist dose on in-vitro fertilisation. Hum Reprod [letter] 1998;13:2973-2974. |